Effective strategies for long-term statin use

American Journal of Cardiology

Volumn 92, Issue 1 SUPPL., 2003, Pages 27-34

  Fonarow, Gregg C ^a   Watson, Karol E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIABETES MELLITUS; DIET; DRUG EFFECT; EXERCISE; GLUCOSE BLOOD LEVEL; HEALTH CARE DELIVERY; HEART PROTECTION; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LONG TERM CARE; MEDICAL ASSESSMENT; MORTALITY; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037627924     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00506-X     Document Type: Article

References (45)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
3. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease a meta-analysis of randomized controlled trials . JAMA. 282:1999;2340-2346.
4. Fonarow G.C., French W.J., Parsons L.S., Sun H., Malmgren J.A. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction data from the National Registry of Myocardial Infarction 3 . Circulation. 103:2001;38-44.
5. Aronow H.D., Topol E.J., Roe M.T., Houghtaling P.L., Wolski K.E., Lincoff A.M., Harrington R.A., Califf R.M., Ohman E.M., Kleiman N.S., et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes an observational study . Lancet. 357:2001;1063-1068.
6. Stenestrand U., Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 285:2001;430-436.
7. Majumdar S.R., Gurwitz J.H., Soumerai S.B. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med. 14:1999;711-717.
8. Sueta C.A., Chowdhury M., Boccuzzi S.J., Smith S.C. Jr, Alexander C.M., Londhe A., Lulla A., Simpson R.J. Jr. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 83:1999;1303-1307.
9. Jacobson T.A., Griffiths G.G., Varas C., Gause D., Sung J.C., Ballantyne C.M. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering drug therapy based on updated NHANES III data. Arch Intern Med. 160:2000;1361-1369.
10. Pearson T.A., Laurora I., Chu H., Kafonek S. The Lipid Treatment Assessment Project (L-TAP) a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals . Arch Intern Med. 160:2000;459-467.
11. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries principal results from EUROASPIRE II Euro Heart Survey Programme . Eur Heart J. 22:2001;554-572.
12. Schrott H.G., Bittner V., Vittinghoff E., Herrington D.M., Hulley S. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease the Heart and Estrogen/Progestin Replacement Study (HERS) . JAMA. 277:1997;1281-1286.
13. Miller M., Byington R., Hunninghake D., Pitt B., Furberg C.D. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Arch Intern Med. 160:2000;343-347.
14. Pearson T.A., Peters T.D., Feury D. The American College of Cardiology Evaluation of Preventive Therapeutics (ACCEPT) study attainment of goals for comprehensive risk reduction in patients with coronary disease in the US . [abstract] J Am Coll Cardiol. 31:1998;186A.
15. American Heart Association. 2003 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2002.
16. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 339:1998;229-234.
17. Malmberg K., Yusuf S., Gerstein H.C., Brown J., Zhao F., Hunt D., Piegas L., Calvin J., Keltai M., Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry . Circulation. 102:2000;1014-1019.
18. Smith S.C. Jr, Blair S.N., Bonow R.O. AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease 2001 update a statement for healthcare professionals from the American Heart Association and the American College of Cardiology . Circulation. 104:2001;1577-1579.
19. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., Mitch W., Smith S.C. Jr, Sowers J.R. Diabetes and cardiovascular disease a statement for healthcare professionals from the American Heart Association . Circulation. 100:1999;1134-1146.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
21. Collins R., Peto R., Armitage J. The MRC/BHF Heart Protection Study preliminary results . Int J Clin Pract. 56:2002;53-56.
22. Lee T.H., Cleeman J.I., Grundy S.M., Gillett C., Pasternak R.C., Seidman J., Sennett C. Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. JAMA. 283:2000;94-98.
23. Pearson T.A., McBride P.E., Miller N.H., Smith S.C. 27th Bethesda Conference matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8: Organization of Preventive Cardiology Service . J Am Coll Cardiol. 27:1996;1039-1047.
24. Fonarow G.C., Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol. 85:(suppl):2000;10A-17A.
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
26. Fonarow G.C. Statin therapy after acute myocardial infarction are we adequately treating high-risk patients? Curr Atheroscler Rep. 4:2002;99-106.
27. Andrade S.E., Walker A.M., Gottlieb L.K., Hollenberg N.K., Testa M.A., Saperia G.M., Platt R. Discontinuation of antihyperlipidemic drugs do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 332:1995;1125-1131.
28. Nelson K., Norris K., Mangione C.M. Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity data from the Third National Health and Nutrition Examination Survey . Arch Intern Med. 162:2002;929-935.
29. Fonarow G.C., Ballantyne C.M. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease the time is now . Circulation. 103:2001;2768-2770.
30. Gore J.M., Goldberg R.J., Matsumoto A.S., Castelli W.P., McNamara P.M., Dalen J.E. Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. Am J Cardiol. 54:1984;722-725.
31. Fonarow G.C., Gawlinski A., Moughrabi S., Tillisch J.H. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 87:2001;819-822.
32. Fonarow G.C., Gawlinski A., Watson K.A., Moughrabi S. Sustained improvement in the treatment of Cardiovascular Hospitalization Atherosclerosis Management Program CHAMP [abstract] . Circulation. 104:2001;II-711.
33. Muhlestein J.B., Horne B.D., Bair T.L., Li Q., Madsen T.E., Pearson R.R., Anderson J.L. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol. 87:2001;257-261.
34. Pearson R.R., Horne B.D., Maycock C.A., Lappe L., Kralick-Goldberg S., Bair T.L., Orton J.A., Wallace D.S., Hanseen H., Renlund D.G., Muhlestein J.B. An institutional discharge medication program reduces future cardiovascular readmissions and mortality an analysis of 43,841 patients with coronary artery disease [abstract] . J Am Coll Cardiol. 39:2002;452A.
35. Cannon C.P., McCabe C.H., Bentley J., Braunwald E. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes observations from OPUS-TIMI-16 . J Am Coll Cardiol. 35:2001;334A.
36. McCarthy M. US heart-guidelines strategy makes promising start. Lancet. 358:2001;1618.
37. Mehta R.H., Montoye C.K., Gallogly M., Baker P., Blount A., Faul J., Roychoudhury C., Borzak S., Fox S., Franklin M., et al. Improving quality of care for acute myocardial infarction the Guidelines Applied in Practice (GAP) Initiative . JAMA. 287:2002;1269-1276.
38. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, et al. ACC/AHA 2002 Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf. Accessed April 1, 2003.
39. DeBusk R.F., Miller N.H., Superko H.R., Dennis C.A., Thomas R.J., Lew H.T., Berger W.E. 3rd, Heller R.S., Rompf J., Gee D., et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 120:1994;721-729.
40. Kinn J.W., Brown A.S. Cardiovascular risk management in clinical practice the Midwest Heart Specialists experience . Am J Cardiol. 89:(suppl):2002;23C-30C.
41. Birtcher K.K., Bowden C., Ballantyne C.M., Huyen M. Strategies for implementing lipid-lowering therapy pharmacy-based approach . Am J Cardiol. 85:(suppl):2000;30A-35A.
42. Blair T.P., Bryant F.J., Bocuzzi S. Treatment of hypercholesterolemia by a clinical nurse using a stepped-care protocol in a nonvolunteer population. Arch Intern Med. 148:1988;1046-1048.
43. Hunninghake D.B. Postdischarge lipid management of coronary artery disease patients according to the new National Cholesterol Education Program guidelines. Am J Cardiol. 88:(suppl):2001;37K-41K.
44. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes the MIRACL study: a randomized controlled trial . JAMA. 285:2001;1711-1718.
45. Brown A.S., Bakker-Arkema R.G., Yellen L., Henley R.W. Jr, Guthrie R., Campbell C.F., Koren M., Woo W., McLain R., Black D.M. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol. 32:1998;665-672.